The impossible made simple!
Conventional microbiology requires laborious amplification to even detect anything. We are the first to introduce a technology that is sensitive enough to simply count the pathogens one by one directly from the sample.
Thanks to our patented nano-electronic biosensor, we are able to detect even one single virus or bacterium, resulting in unprecedented sensitivity. We identify the targeted pathogen and disregard other components in the sample, for superior specificity. This gives you better insights to make the right diagnosis and determine the correct regimen.
The test is performed as close as possible to the patient. The data is brought as close as possible to the clinician, through the cloud. This ensures a secure mode of communication between the medical professional in the ER, OR, ICU and GP’s office and the microbiologist in the lab.
We significantly reduced the logistical complexity of a diagnosis. Less hands-on time, easy-to-use for all practitioners, online accessible, resulting in an effective and cost efficient procedure.
Company Details
- Employees
- 4
- Founded
- -
- Address
- Hallenweg 23, Cr 1439,netherlands
- Industry
- Nanotechnology Research
- NAICS
-
Research and Development in Nanotechnology
- Website
- ecsens.com
- HQ
- Enschede, Overijssel
Occam Dx Questions
Occam Dx's website is ecsens.com
Occam Dx's LinkedIn profile is https://nl.linkedin.com/company/occamdx
Occam Dx has
4 employees.
View email and phone details for 4
employees at Occam Dx.
Occam Dx's industry is
Nanotechnology Research
Occam Dx's top competitors are
Nanomi,
Solstice Pharmaceuticals B.v.,
Medspray Bv,
Dolomite Microfluidics,
Emultech,
River Biomedics,
Vycap,
Lipocoat,
Iamfluidics,
Uneedle.
Occam Dx's categories are Nanotechnology Research
Occam Dx's founding year is 2019
